Sarepta Therapeutics is a biotechnology company that develops RNA-based and gene therapies for rare neuromuscular diseases, notably Duchenne muscular dystrophy.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Howard Marks / Oaktree | 71 | New buy | 6,709,000 | $6,344,687 | 0.1% |
| Steve Cohen / Point72 | 76 | Added +1548% | 510,908 | $9,181,017 | 0.0% |
| Bridgewater | 56 | Added +13% | 152,068 | $2,732,662 | 0.0% |
| Ancora | 40 | Trimmed -42% | 2,500 | $44,925 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-09-22 | Trump, Donald J President | SELL | $15,001 - $50,000 | PTR |
| 2026-08-22 | Trump, Donald J President | SELL | $15,001 - $50,000 | PTR |
| 2026-05-14 | Trump, Donald J President | BUY | $15,004 - $50,000 | PTR |
| 2026-05-14 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.